Literature DB >> 22127200

Depression in women: windows of vulnerability and new insights into the link between estrogen and serotonin.

Sonali Lokuge, Benicio N Frey, Jane A Foster, Claudio N Soares, Meir Steiner.   

Abstract

OBJECTIVE: The purpose of this commentary is to provide an update on the research in both preclinical and clinical models regarding the cross-talk between estrogen and various serotonin molecular markers and the possible implications this may have on female-related mood disorders.
CONCLUSIONS: Animal and human studies provide strong and consistent evidence suggesting that estrogen is able to regulate the serotonin pathway at various levels. The general trend that emerges is that estrogen administration increases serotonin availability by altering mRNA and protein levels of various serotonin markers and by decreasing serotonin breakdown. These effects may have direct implications on female mood disorders such as premenstrual disorders and depression during pregnancy, postpartum, and during the menopausal transition. © Copyright 2011 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22127200     DOI: 10.4088/JCP.11com07089

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  25 in total

1.  Lifelong estradiol exposure and risk of depressive symptoms during the transition to menopause and postmenopause.

Authors:  Wendy K Marsh; Joyce T Bromberger; Sybil L Crawford; Katherine Leung; Howard M Kravitz; John F Randolph; Hadine Joffe; Claudio N Soares
Journal:  Menopause       Date:  2017-12       Impact factor: 2.953

2.  Methodological considerations in assessing the effectiveness of antidepressant medication continuation during pregnancy using administrative data.

Authors:  Sonja A Swanson; Sonia Hernandez-Diaz; Kristin Palmsten; Helen Mogun; Mark Olfson; Krista F Huybrechts
Journal:  Pharmacoepidemiol Drug Saf       Date:  2015-06-04       Impact factor: 2.890

3.  Transdermal Estradiol Treatment for Postpartum Depression: A Pilot, Randomized Trial.

Authors:  Katherine L Wisner; Dorothy K Y Sit; Eydie L Moses-Kolko; Kara E Driscoll; Beth A Prairie; Catherine S Stika; Heather F Eng; John L Dills; James F Luther; Stephen R Wisniewski
Journal:  J Clin Psychopharmacol       Date:  2015-08       Impact factor: 3.153

4.  Examination of premenstrual symptoms as a risk factor for depression in postpartum women.

Authors:  Melissa M Buttner; Sarah L Mott; Teri Pearlstein; Scott Stuart; Caron Zlotnick; Michael W O'Hara
Journal:  Arch Womens Ment Health       Date:  2013-01-08       Impact factor: 3.633

5.  Gender and age interact to predict the development of posttraumatic stress disorder symptoms following a motor vehicle accident.

Authors:  Ihori Kobayashi; Eve M Sledjeski; Douglas L Delahanty
Journal:  Psychol Trauma       Date:  2018-02-15

6.  Hormone therapy use in women veterans accessing veterans health administration care: a national cross-sectional study.

Authors:  Megan R Gerber; Matthew W King; Suzanne L Pineles; Shannon Wiltsey-Stirman; Bevanne Bean-Mayberry; Sandra J Japuntich; Sally G Haskell
Journal:  J Gen Intern Med       Date:  2014-11-06       Impact factor: 5.128

7.  Insomnia, postpartum depression and estradiol in women after delivery.

Authors:  Ewa Drozdowicz-Jastrzębska; Michał Skalski; Paulina Gdańska; Anna Mach; Piotr Januszko; Rafał J Nowak; Piotr Węgrzyn; Mirosław Wielgoś; Maria Radziwoń-Zaleska
Journal:  Metab Brain Dis       Date:  2017-08-08       Impact factor: 3.584

8.  Association study of the estrogen receptor gene ESR1 with postpartum depression--a pilot study.

Authors:  Julia K Pinsonneault; Danielle Sullivan; Wolfgang Sadee; Claudio N Soares; Elizabeth Hampson; Meir Steiner
Journal:  Arch Womens Ment Health       Date:  2013-08-07       Impact factor: 3.633

9.  History of postpartum depression in a clinic-based sample of women with premenstrual dysphoric disorder.

Authors:  Alyson L Kepple; Ellen E Lee; Nazli Haq; David R Rubinow; Peter J Schmidt
Journal:  J Clin Psychiatry       Date:  2016-04       Impact factor: 4.384

10.  Luteal phase and symptom-onset dosing of SSRIs/SNRIs in the treatment of premenstrual dysphoria: clinical evidence and rationale.

Authors:  Meir Steiner; Tina Li
Journal:  CNS Drugs       Date:  2013-08       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.